Evidence map›Paper›PMID 26556867›Full record

ArticleOncotarget2015

Growth-stimulatory activity of TIMP-2 is mediated through c-Src activation followed by activation of FAK, PI3-kinase/AKT, and ERK1/2 independent of MMP inhibition in lung adenocarcinoma cells.

Han Ie Kim, Hyun-Sung Lee, Tae Hyun Kim, Ju-Seog Lee, Seung-Taek Lee, Seo-Jin Lee

Open access · diamondAbstract read
In one paragraph

Article in Oncotarget, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.4field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 24 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 2 countries.

Han Ie KimDepartment of Life Science & Biotechnology, Shingyeong University, Gyeonggi-do, 445-741, Republic of Korea.
Hyun-Sung LeeDivision of Thoracic Surgery, Michael E. DeBakey Department of Surgery, Baylor College of Medicine, Houston, TX, 77030, U.S.A.
Tae Hyun KimDepartment of Life Science & Biotechnology, Shingyeong University, Gyeonggi-do, 445-741, Republic of Korea.
Ju-Seog LeeDepartment of Systems Biology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 77054, U.S.A.
Seung-Taek LeeDepartment of Biochemistry, College of Life Science and Biotechnology, Yonsei University, Seoul, 120-749, Republic of Korea.
Seo-Jin LeeDepartment of Life Science & Biotechnology, Shingyeong University, Gyeonggi-do, 445-741, Republic of Korea.
Shingyeong University · KRYonsei University · KRBaylor College of Medicine · USThe University of Texas MD Anderson Cancer Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tissue inhibitors of metalloproteinases (TIMPs) control extracellular matrix (ECM) homeostasis by inhibiting the activity of matrix metalloproteinases (MMPs), which are associated with ECM turnover. Recent studies have revealed that TIMPs are implicated in tumorigenesis in both MMP-dependent and MMP-independent manners. We examined a mechanism by which TIMP-2 stimulated lung adenocarcinoma cell proliferation, independent of MMP inhibition. The stimulation of growth by TIMP-2 in A549 cells required c-Src kinase activation. c-Src kinase activity, induced by TIMP-2, concomitantly increased FAK, phosphoinositide 3-kinase (PI3-kinase)/AKT, and ERK1/2 activation. Selective knockdown of integrin α3β1, known as a TIMP-2 receptor, did not significantly change TIMP-2 growth promoting activity. Furthermore, we showed that high TIMP-2 expression in lung adenocarcinomas is associated with a worse prognosis from multiple cohorts, especially for stage I lung adenocarcinoma. Through integrated analysis of The Cancer Genome Atlas data, TIMP-2 expression was significantly associated with the alteration of driving genes, c-Src activation, and PI3-kinase/AKT pathway activation. Taken together, our results demonstrate that TIMP-2 stimulates lung adenocarcinoma cell proliferation through c-Src, FAK, PI3-kinase/AKT, and ERK1/2 pathway activation in an MMP-independent manner.

Indexed as

AdenocarcinomaBlotting, WesternCell Line, TumorCell ProliferationCSK Tyrosine-Protein KinaseEnzyme ActivationFocal Adhesion Kinase 1Gene Expression Regulation, NeoplasticGene Knockdown TechniquesHumansKaplan-Meier EstimateLung NeoplasmsMAP Kinase Signaling SystemMatrix MetalloproteinasesMutagenesis, Site-DirectedPhosphatidylinositol 3-KinasesCSK protein, humanCSK Tyrosine-Protein KinaseFocal Adhesion Kinase 1Matrix MetalloproteinasesPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktPTK2 protein, humansrc-Family KinasesTIMP2 protein, humanTissue Inhibitor of Metalloproteinase-2c-Srclung adenocarcinomaPI3-kinase/AKT pathwayTIMPstumorigenesis

Identifiers

PMID26556867
PMCPMC4767480
OpenAlexW2119231679

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.